These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 7997539)
1. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Boland GW; Goldberg MA; Lee MJ; Mayo-Smith WW; Dixon J; McNicholas MM; Mueller PR Radiology; 1995 Jan; 194(1):131-4. PubMed ID: 7997539 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444 [TBL] [Abstract][Full Text] [Related]
3. [Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions]. Maurea S; Mainolfi C; Wang H; Varrella P; Panico MR; Klain M; Rossi R; Cremona F; Bazzicalupo L; Salvatore M Radiol Med; 1996 Dec; 92(6):782-7. PubMed ID: 9122472 [TBL] [Abstract][Full Text] [Related]
4. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920 [TBL] [Abstract][Full Text] [Related]
5. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose. Martin WH; Delbeke D; Patton JA; Sandler MP Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384 [TBL] [Abstract][Full Text] [Related]
6. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536 [TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. Kumar R; Xiu Y; Yu JQ; Takalkar A; El-Haddad G; Potenta S; Kung J; Zhuang H; Alavi A J Nucl Med; 2004 Dec; 45(12):2058-62. PubMed ID: 15585482 [TBL] [Abstract][Full Text] [Related]
18. The value of 18F-FDG PET-CT and 131I-norcholesterol scintigraphy in the characterization of high-risk adrenal masses. Riaz S; Syed R; Aziz TA; Alnaim A; Chung TT; Wan S; Kurzawinski TR; Bomanji J Nucl Med Commun; 2020 Mar; 41(3):189-195. PubMed ID: 31895761 [TBL] [Abstract][Full Text] [Related]
19. Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans. Zasadny KR; Kison PV; Quint LE; Wahl RL Radiology; 1996 Dec; 201(3):873-6. PubMed ID: 8939245 [TBL] [Abstract][Full Text] [Related]
20. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Shulkin BL; Koeppe RA; Francis IR; Deeb GM; Lloyd RV; Thompson NW Radiology; 1993 Mar; 186(3):711-5. PubMed ID: 8430179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]